Mei Huang

Holistic Medicine
200 B St
Suite B
Davis, CA 95616

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Journal: Blood
Published: December 02, 2025

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Journal: EJHaem
Published: December 18, 2023

The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux.

The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux.

Journal: Behavioural brain research
Published: August 16, 2023

NU-1223, a simplified analog of alstonine, with 5-HT2cR agonist-like activity, rescues memory deficit and positive and negative symptoms in subchronic phencyclidine mouse model of schizophrenia.

NU-1223, a simplified analog of alstonine, with 5-HT2cR agonist-like activity, rescues memory deficit and positive and negative symptoms in subchronic phencyclidine mouse model of schizophrenia.

Journal: Behavioural brain research
Published: March 27, 2023

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.

Journal: HemaSphere
Published: March 22, 2023

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.

Journal: Haematologica
Published: March 09, 2023

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.

Journal: Blood advances
Published: November 10, 2022

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.

Journal: Cancer cell
Published: October 24, 2022

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.

Journal: Leukemia
Published: April 08, 2022

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

Journal: The New England journal of medicine
Published: March 16, 2022

Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice.

Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice.

Journal: Behavioural brain research
Published: February 21, 2022

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study.

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study.

Journal: Journal of clinical medicine
Published: November 12, 2021
Showing 1-12 of 49

Last Updated: 09/26/2026